Close
ACHEMA MIDDLE EAST 2026

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

AI Summary

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.

Dr Ryan Cawood, CEO of Oxford Genetics said, “This license agreement with Twist Bioscience serves as further recognition of our approach to developing the best optimised expression vectors. By utilising our SnapFast™ platform, Twist Bioscience is giving its customers access to the latest vector designs for the most demanding applications and providing them with better value, a streamlined workflow and maximum flexibility in order to utilise their custom DNA constructs to their best effect.”

Oxford Genetics specialises in the design of application specific vectors, which is a culmination of access to cutting edge bioinformatics, generation of extensive biological data, and continual refinement to ensure customer success. The vectors also grant access to the wider SnapFast™ ecosystem which allows Twist Bioscience to switch between all of Oxford Genetics’ vectors, making future changes and additions simple and efficient.

Emily M. Leproust, Ph.D., CEO of Twist Bioscience commented, “By complementing our ability to provide high throughput synthetic genes with a wide range of customized vectors from Oxford Genetics, we accelerate our customer’s workflow, allowing them to solve more complex problems while saving both time and resources. Importantly, it enables us to reach the large group of customers who order smaller quantities of genes in standard vectors. We remain committed to optimizing our product line to enable our customers to succeed more quickly.”

The pharmaceutical industry rarely announces its most significant shifts loudly. The signals are there — if you know where to look.

The Pharma Advancement briefing is how the sector’s most informed professionals stay ahead of those signals — covering drug development, regulatory affairs, manufacturing, and market access across every major region.

  • The stories pharmaceutical professionals will be discussing tomorrow, in your inbox today
  • Analysis that goes beyond the headline — written for readers who already understand the industry
  • The briefing that the sector’s most informed professionals open first

SUBSCRIBE OUR NEWSLETTER

WHITE PAPERS

RELATED ARTICLES